Initiate studies to develop minimally invasive biomarkers for detection of cerebral amyloidosis, AD and AD-related dementias pathophysiology.
Development and testing of at least 3 biomarkers that utilize biofluids or other minimally invasive imaging, electrophysiological recording, or other methodologies to assess the burden of AD and ADRD pathophysiology that could be used in community based and epidemiological studies of AD and related dementias.
2015 to 2023
Research Implementation Area
B. Diagnosis, Assessment and Disease Monitoring
Activities, Funding Initiatives, and Resources
NIH PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting…
NIH RFA-AG-15-011: Biomarkers of Alzheimer’s Disease in Down Syndrome (R01)
PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting Pro…
NNIH RFA-AG-15-011: Biomarkers of Alzheimer's Disease in Down Syndrome (R01)
NIH PA-16-091: Small Business Alzheimer's Disease Research (R43/R44)
NIH PA-16-092: Small Business Alzheimer's Disease Research (R41/R42)
NIH RFA-AG-16-019: Limited Competition: Alzheimer's Disease Neuroimaging Initia…
NIH PAR-18-183: T1 Translational Research on Aging: Small Business Innovation A…
NIH PAS-18-188: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-…